Gauging the impact of statins using number needed to treat

JAMA

Volumn 282, Issue 20, 1999, Pages 1899-1901

  Kumana, C R ^a   Cheung, B M Y ^a   Lauder, I J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ADULT; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SMOKING;

EID: 0033601078     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.20.1899     Document Type: Review

References (18)

1. Abramowicz M, ed. Fluvastatin for lowering cholesterol. Med Lett Drugs Ther. 1994;36:45-48.
2. Simons LA, Barter P. New guidelines for the use of lipid-lowering drugs. In: Insert to the Australian Schedule of Pharmaceutical Benefits. December 1994.
3. Joint Formulary Committee Lipid-lowering drugs. Br Natl Formulary. 1995;29:107-111.
4. Ose L, Scott R, and the Simvastatin-Fluvastatin Study Group. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolemia. Clin Drug Invest 1995;10:127-138.
5. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
6. Adult Treatment Panel II National Cholesterol Education Program (NCEP) Second Report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;89:1329-1414.
7. Abramowicz M, ed. Choice of lipid-lowering drugs. Med Lett Drugs Ther. 1996;38:67-70.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;334:1383-1389.
9. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 1995; 333:1301-1307.
10. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
11. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med. 1998;339:1349-1357.
12. Owns JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in man and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1628.
13. Kumana CR, Lauder IJ. Appraising published claims about drug treatment to implement best therapy in clinical practice. Hong Kong Med J. 1998;4:158-168.
14. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin. Circulation. 1999;99:216-223.
15. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
16. Sourander L, Rajala T, Raiha I, et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on estrogen replacement therapy (ERT). Lancet. 1998;352:1965-1969.
17. Hulley S, Grady D, Bush T, et al, for the HERS Research Group. Randomized trail of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280: 605-613.
18. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA. 1998;280:650-652.